Listed

Angiodynamics Inc: Form 10-Q for the period ended Nov 30, 2017

Filed with the SEC on Jan 5, 2018 and accepted by EDGAR at Jan 5, 2018, 15:35 ET.

Share

Management's discussion and analysis

As filed, 33,071 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

Forward-Looking Statements

This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as our ability to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

EXECUTIVE OVERVIEW

Company and Market

We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Most of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or longer-term use.

Our business operations cross a variety of markets. Our financial performance is impacted by changing market dynamics, which have included an emergence of value-based purchasing by healthcare providers, consolidation of healthcare providers, the increased role of the consumer in health care decision-making and an aging population, among others. In addition, our growth is impacted by changes within our sector, such as the merging of competitors to gain scale and influence; changes in the regulatory environment for medical devices; and fluctuations in the global economy.

Our sales and profitability growth also depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions to our product offerings are created through internal product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in, research and development activities and business development opportunities. We feel confident that our existing capital structure and free cash flow generation will allow us to properly fund those activities.

We sell our products in the United States primarily through a direct sales force, and outside the U.S. through a combination of a direct sales and distributor relationships. We expect our businesses to grow in both sales and profitability through geographic expansion, market penetration, new product introductions and increasing our direct presence internationally.

In evaluating the operating performance of our business, management focuses on revenue, gross margin, operating income, earnings per share and cash flow from operations. A summary of these key financial metrics for the three and six months ended November 30, 2017 compared to the three and six months ended November 30, 2016:

Three months ended November 30, 2017:

  • Revenue decreased by 2.6% to $86.7 million
  • Gross margin as a percentage of sales decreased by 1.3% to 49.3%
  • Operating income decreased by $14.5 million to $1.1 million
  • Earnings per share decreased by $0.36 to $0.01

Six months ended November 30, 2017:

  • Revenue decreased by 2.8% to $172.1 million
  • Gross margin as a percentage of sales decreased by 2.0% to 48.8%
  • Operating income decreased by $17.9 million to $1.3 million
  • Earnings per share decreased by $0.40 to $0.01
  • Cash flow from operations decreased by $9.2 million to $13.2 million

The decline in revenue during the second quarter was primarily driven by declines in Venous and Core within Peripheral Vascular and non-BioFlo products within Vascular Access.

The decline was partially offset by 8% growth in the Oncology/Surgery Global Business Unit primarily as a result of sales associated with Solero, a microwave ablation device that received FDA clearance during the second quarter of fiscal year 2018. Other areas of growth include Fluid Management and Thrombus Management within Peripheral Vascular and the BioFlo family of products within Vascular Access.

New Accounting Pronouncements

Information regarding new accounting pronouncements is included in Note 15 to our consolidated financial statements in this Quarterly Report on Form 10-Q.

Results of Operations for the Three Months ended November 30, 2017 and 2016

For the three months ended November 30, 2017, we reported net income of $0.2 million, or $0.01 per diluted share, on net sales of $86.7 million, compared with net income of $13.7 million, or $0.37 per share, on net sales of $89.0 million during the same quarter of the prior year.

Net Sales

Net sales - Net sales are derived from the sale of our products and related freight charges, less discounts and returns.

Net sales for the three months ended November 30, 2017 and 2016:

Net Sales by Product Category Three months ended Nov 30, 2017 Nov 30, 2016 % Growth
Peripheral Vascular $51,368 $53,696 (4)%
Vascular Access 22,574 23,553 (4)%
Oncology/Surgery 12,764 11,780 8%
Total $86,706 $89,029 (3)%
Net Sales by Geography
United States $68,301 $71,431 (4)%
International 18,405 17,598 5%
Total $86,706 $89,029 (3)%

For the three months ended November 30, 2017, net sales decreased $2.3 million to $86.7 million compared to the same period in the prior year.

  • Consolidated and U.S. net sales decreased from the prior year as a result of lower net sales from Peripheral Vascular and Vascular Access. This decrease was partially offset by 8% year over year growth in our Oncology/Surgery Global Business Unit.

Peripheral Vascular

  • Total Peripheral Vascular sales decreased $2.3 million primarily attributable to decreased sales volume of Venous and Angiographic products of $3.0 million. The decrease in our Venous product line of $2.1 million is due to reimbursement challenges. The decrease in our Angiographic product line of $0.9 million is related to the prior year volume from backorders related to a competitor recall. These decreases were offset by strong performance in our Fluid Management product line, which increased $0.5 million year over year. The increase in Fluid Management was attributed to the Fluid Management dedicated sales team being fully staffed and promoting new custom kits.
  • U.S. Peripheral Vascular sales decreased $2.1 million and international Peripheral Vascular sales decreased $0.2 million, which was primarily due to decreased sales volume of Venous and Angiographic products. This decreased sales volume was offset by an increase in volume in Fluid Management and Thrombus Management categories.

Vascular Access

  • Total Vascular Access sales decreased $1.0 million primarily in our non-BioFlo businesses. Our BioFlo product lines grew 2% year over year and now comprise 49% of our overall vascular access sales, compared to 46% a year ago.
  • U.S. Vascular Access sales declined by 5% due to softness across the portfolio offset by Midline and BioFlo Dialysis which continue to gain traction in the marketplace.
  • International Vascular Access sales increased by $0.1 million due to focus in the Latin America region.

Oncology/Surgery

  • Total Oncology/Surgery sales increased $1.0 million year over year primarily due to the successful launch of our Solero product line, which generated $1.7 million of growth year over year. This was offset by decreased sales in Radiofrequency Ablation and NanoKnife disposables.
  • U.S. Oncology/Surgery increased by 1%, driven by Solero Microwave capital and disposable sales, partially offset by decreased sales in Radiofrequency Ablation and NanoKnife disposables.
  • International Oncology/Surgery sales increased by $0.9 million year over year as a result of Solero Microwave capital and disposable sales of $2.8 million.

Gross Profit, Operating expenses, and Other income (expense)

Three months ended Nov 30, 2017 Nov 30, 2016 % Change
Gross profit $42.7 $45.0 (5)%
Gross profit % of sales 49.3% 50.6%
Research and development $6.1 $5.9 3%
% of sales 7.0% 6.6%
Selling and marketing $19.0 $19.5 (3)%
% of sales 21.9% 21.9%
General and administrative $7.5 $7.8 (4)%
% of sales 8.7% 8.8%

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.

Gross profit decreased by $2.3 million compared to the prior year. The decrease is attributable to the following:

  • In second quarter of fiscal year 2018, the Company decided to discontinue selling our Radiofrequency Ablation product in Japan which resulted in a $1.7 million inventory provision. Volume softness and pricing headwinds of approximately 1% were offset by the expiration of a royalty agreement that was accrued and paid monthly.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.

R&D expense increased $0.2 million compared to the prior year. The increase is attributable to the following:

  • Timing of project spend in the second quarter of fiscal year 2018 compared to prior year was up $0.4 million.
  • R&D expense as a percentage of sales increased slightly year over year as a result of the higher R&D expense along with lower sales in the second quarter of fiscal year 2018.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.

S&M expense decreased by $0.5 million compared to the prior year. The decrease is attributable to the following:

  • A decrease in compensation and benefits of approximately $0.3 million, which was primarily the result of decreased variable compensation of $0.7 million offset by severance of $0.4 million.
  • Lower consulting spend of $0.3 million.
  • The percentage of S&M to sales remained consistent year over year.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.

G&A expense decreased by $0.3 million compared to the prior year. The decrease is attributable to the following:

  • Lower depreciation of $0.2 million, professional fees of $0.1 million offset slightly by an increase in compensation and benefits.
Three months ended Nov 30, 2017 Nov 30, 2016 $ Change
Amortization of intangibles $4.1 $4.3 $(0.2)
Change in fair value of contingent consideration $0.1 $(16.0) $16.1
Acquisition, restructuring and other items, net $4.8 $7.9 $(3.1)
Other expense $(1.0) $(1.2) $0.2

Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.

  • The decrease of $0.2 million is primarily related to intangible assets that became fully amortized.

Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.

  • The decrease is due to the fact that in the second quarter of fiscal year 2017 the future sales projections for the AngioVac product were updated which resulted in the elimination of any payments above minimums. The normal amortization of the present value discount on the contingent liabilities is now approximately $0.1 million per quarter.

Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.

Acquisition, restructuring and other items, net decreased by $3.1 million compared to the prior year. The decrease is attributable to the following:

  • In the prior year there was a $2.0 million write-off of Embomedics due to termination of the agreement and $3.6 million related to the decision to discontinue our investment in the TiLo product.
  • There was $1.4 million of expense related to the plant consolidation that was announced in the third quarter of fiscal year 2017. The expense consisted mainly of severance of $0.6 million and start-up costs to move the product lines including equipment transfer expenses, accelerated depreciation for assets that will not be transferred, validation and other start up costs of $0.8 million.
  • Legal expenses of $3.2 million were recorded in the current year compared to $1.8 million in the prior year.

Other expenses - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.

  • Other expenses remained consistent year over year.

Income Tax Provision (Benefit)

Three months ended Nov 30, 2017 Nov 30, 2016
Income tax expense (benefit) $(0.2) $0.7
Effective tax rate including discrete items (200.0)% 4.7%

Our effective tax rate including discrete items for the three month periods ended November 30, 2017 and 2016 was (200.00)% and 4.72%, respectively.

The estimated annual effective tax rate, however, prior to discrete items was 59.8% in the second quarter of fiscal 2018, as compared to 47.3% for the same period in fiscal 2017. The Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the deferred tax liability related to indefinite lived intangibles, valuation allowance, foreign taxes and state taxes.

A valuation allowance is established if it is more likely than not that all, or a portion of the deferred tax asset will not be realized. The Company has established that it is more likely than not that some, or all of their deferred tax assets will not be recognized in future years. Consequently, the Company continues to maintain a full U.S. valuation allowance on its net deferred tax assets. Management will continue to reevaluate the positive and negative evidence at each reporting period and if future results as projected in the U.S. and our tax planning strategies are favorable, the valuation allowance may be removed, which could have a favorable material impact on our results of operations in the period in which it is recorded.

Subsequent to the quarter ended November 30, 2017, the “Tax Cuts and Jobs Act” was enacted on December 22, 2017, and is effective for tax periods beginning on January 1, 2018. The enactment of this legislation would result in a significant tax benefit of approximately $9.3 million recorded in the period of enactment, principally related to the reduction of the corporate income tax rate from 35% to 21% and its effect on its deferred tax liability of long-lived intangibles. As of May 31, 2017, the gross taxable temporary difference related to long-lived intangibles was $71.8 million. The Company maintains a full U.S. valuation allowance on all of its other net deferred tax assets and the legislation is not expected to have a material impact.

Results of Operations for the Six Months ended November 30, 2017 and 2016

For the six months ended November 30, 2017, we reported a net income of $0.2 million, or $0.01 per diluted share, on net sales of $172.1 million, compared with net income of $15.0 million, or $0.41 per share, on net sales of $177.1 million during the same quarter of the prior year.

Net Sales

Net sales - Net sales are derived from the sale of our products and related freight charges, less discounts and returns.

Net sales for the six months ended November 30, 2017 and 2016:

Net Sales by Product Category Six months ended Nov 30, 2017 Nov 30, 2016 % Growth
Peripheral Vascular $101,234 $105,725 (4)%
Vascular Access 45,812 48,558 (6)%
Oncology/Surgery 25,071 22,844 10%
Total $172,117 $177,127 (3)%
Net Sales by Geography
United States $137,232 $143,638 (4)%
International 34,885 33,489 4%
Total $172,117 $177,127 (3)%

For the six months ended November 30, 2017, net sales decreased $5.0 million to $172.1 million compared to the same period in the prior year.

  • Consolidated and U.S. net sales decreased from the prior year as a result of decreased net sales from Peripheral Vascular and Vascular Access. This decrease was partially offset by 10% year over year growth in our Oncology/Surgery Global Business Unit.

Peripheral Vascular

  • Total Peripheral Vascular sales decreased $4.5 million primarily attributable to decreased sales volume of Venous and Angiographic products of $6.2 million. The decrease in our Venous product line of $3.5 million is due to reimbursement challenges. The decrease in our Angiographic product line of $2.7 million is related to the prior year volume from backorders related to a competitor recall. These decreases were offset by strong performance in our

Fluid Management product line, which increased $1.6 million year over year. The increase in Fluid Management was attributed to the Fluid Management dedicated sales team being fully staffed and promoting new custom kits.

  • U.S. Peripheral Vascular sales decreased $3.5 million and international Peripheral Vascular sales decreased $1.0 million, which was primarily due to decreased sales volume of Venous and Angiographic core products. This decreased sales volume was offset by an increase in volume in Fluid Management and Thrombus Management categories.

Vascular Access

  • Total Vascular Access sales decreased $2.7 million primarily due to declines in our non-BioFlo businesses. Our BioFlo product lines grew 2% year over year and now comprise 49% of our overall vascular access sales, compared to 45% a year ago.
  • U.S. Vascular Access sales declined by 6% due to softness across the portfolio offset by Midline and BioFlo Dialysis which continue to gain traction in the marketplace.
  • International Vascular Access sales decreased by $0.4 million which was due to market challenges across most product lines.

Oncology/Surgery

  • Total Oncology/Surgery sales increased $2.2 million year over year primarily due to the successful launch of our Solero product line, which generated $3.2 million of growth year over year.
  • U.S. Oncology/Surgery declined by 4%, driven primarily by the timing of NanoKnife capital and disposable sales of $1.1 million and market challenges in the Radiofrequency Ablation product line of $1.0 million partially offset by increased Microwave capital and disposable sales of $1.3 million.
  • International Oncology/Surgery sales increased $2.6 million year over year as a result of Microwave capital and disposable sales of $5.5 million.

Gross Profit, Operating expenses, and Other income (expense)

Six months ended Nov 30, 2017 Nov 30, 2016 % Change
Gross profit $84.0 $90.0 (7)%
Gross profit % of sales 48.8% 50.8%
Research and development $12.6 $12.6 —%
% of sales 7.3% 7.1%
Selling and marketing $38.4 $38.9 (1)%
% of sales 22.3% 22.0%
General and administrative $15.6 $16.0 (3)%
% of sales 9.1% 9.1%

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.

Gross profit decreased by $6.0 million compared to the prior year. The decrease is attributable to the following:

  • In second quarter of fiscal year 2018, the Company decided to discontinue selling our Radiofrequency Ablation product in Japan which resulted in a $1.7 million inventory provision. Volume softness, product mix and pricing headwinds of approximately 1% were offset by the expiration of a royalty agreement and net productivity.

Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.

R&D expense remained consistent year over year.

  • Higher project spend of $0.3 million in fiscal year 2018 was partially offset by open headcount.
  • R&D expense as a percentage of sales increased slightly year over year as a result of lower sales in the second quarter of fiscal year 2018.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.

S&M expense decreased by $0.6 million compared to the prior year. The decrease is attributable to the following:

  • A decrease in compensation and benefits of approximately $0.9 million, which was primarily the result of decreased variable compensation of $1.4 million offset by severance of $0.6 million.
  • Decreases in consulting of $0.3 million were partially offset by increased travel of clinical specialists of $0.2 million and increased samples expense related to Solero of $0.2 million.
  • The percentage of S&M to sales remained consistent year over year.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.

G&A expense decreased by $0.4 million compared to the prior year. The decrease is attributable to the following:

  • Lower recruiting and relocation expenses of $0.4 million, lower depreciation expense of $0.4 million offset by $0.3 million in increased professional fees.
Six months ended Nov 30, 2017 Nov 30, 2016 $ Change
Amortization of intangibles $8.2 $8.5 $(0.3)
Change in fair value of contingent consideration $0.2 $(15.5) $15.7
Acquisition, restructuring and other items, net $7.8 $10.3 $(2.5)
Other expense $(1.2) $(1.8) $0.6

Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.

  • The decrease of $0.3 million is primarily related to intangible assets that became fully amortized.

Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.

  • The decrease is due to the fact that in the second quarter of fiscal year 2017 the future sales projections for the AngioVac product were updated which resulted in the elimination of any payments above minimums. The normal amortization of the present value discount on the contingent liabilities is now approximately $0.1 million per quarter.

Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.

Acquisition, restructuring and other items, net decreased by $2.5 million compared to the prior year. The decrease is attributable to the following:

  • In the prior year there was a $2.0 million write-off of Embomedics due to termination of the agreement and $3.6 million related to the decision to discontinue our investment in the TiLo product.
  • There was $2.6 million of expense related to the plant consolidation that was announced in the third quarter of fiscal year 2017. The expense consisted mainly of severance of $1.1 million and start-up costs to move the product lines including equipment transfer expenses, accelerated depreciation for assets that will not be transferred, validation and other start up costs of $1.4 million.
  • Legal expenses of $5.0 million were recorded in the current year compared to $3.6 million in the prior year.

Other expenses - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.

  • The decrease in other expenses of $0.6 million was due to unrealized foreign currency gains from re-measurement.

Income Tax Provision (Benefit)

Six months ended Nov 30, 2017 Nov 30, 2016
Income tax expense (benefit) $(0.1) $2.3
Effective tax rate including discrete items (219.4)% 13.2%

Our effective tax rate including discrete items for the six month periods ended November 30, 2017 and 2016 was (219.4)% and 13.2%, respectively.

The estimated annual effective tax rate, however, prior to discrete items was 59.8% in the second quarter of fiscal 2018, as compared to 47.3% for the same period in fiscal 2017. The Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the deferred tax liability related to indefinite lived intangibles, valuation allowance, foreign taxes and state taxes.

A valuation allowance is established if it is more likely than not that all, or a portion of the deferred tax asset will not be realized. The Company has established that it is more likely than not that some, or all of their deferred tax assets will not be recognized in future years. Consequently, the Company continues to maintain a full U.S. valuation allowance on its net deferred tax assets. Management will continue to reevaluate the positive and negative evidence at each reporting period and if future results as projected in the U.S. and our tax planning strategies are favorable, the valuation allowance may be removed, which could have a favorable material impact on our results of operations in the period in which it is recorded.

Subsequent to the quarter ended November 30, 2017, the “Tax Cuts and Jobs Act” was enacted on December 22, 2017, and is effective for tax periods beginning on January 1, 2018. The enactment of this legislation would result in a significant tax benefit of approximately $9.3 million recorded in the period of enactment, principally related to the reduction of the corporate income tax rate from 35% to 21% and its effect on its deferred tax liability of long-lived intangibles. As of May 31, 2017, the gross taxable temporary difference related to long-lived intangibles was $71.8 million. The Company maintains a full U.S. valuation allowance on all of its other net deferred tax assets and the legislation is not expected to have a material impact.

Liquidity and Capital Resources

Our cash and cash equivalents totaled $49.9 million as of November 30, 2017, compared with $47.5 million as of May 31, 2017. Marketable securities totaled $1.3 million as of November 30, 2017 and $1.2 million as of May 31, 2017, and consist of an auction rate security. As of November 30, 2017, total principal debt outstanding was $95.0 million and the fair value of contingent consideration payments was $3.2 million.

The table below summarizes our cash flows for the six months ended November 30, 2017 and 2016:

(in thousands)

Cash provided by (used in): Six Months Ended Nov 30, 2017 Nov 30, 2016
Operating activities $13,201 $22,387
Investing activities (1,222) (1,396)
Financing activities (10,262) (17,402)
Effect of exchange rate changes on cash and cash equivalents 595 (258)
Net change in cash and cash equivalents $2,312 $3,331

During the six months ended November 30, 2017 and 2016, cash flows consisted of the following:

Cash provided by operating activities

  • With regards to working capital, the Company continues to focus on optimizing days sales outstanding (DSO) which contributed to $2.3 million of working capital improvement. This working capital improvement was offset by $4.5 million of higher payments for accounts payable and accrued liabilities from May 31, 2017 through November 30, 2017.

Cash used in investing activities

  • $1.2 million in fixed asset additions compared to $1.8 million in the prior year.

Cash used in financing activities

  • $2.5 million in repayments on long-term debt in the first six months of fiscal year 2018 compared to $5.0 million in the first six months of fiscal year 2017 consistent with the required amortization payment on Term Loan A.
  • $1.7 million of proceeds from stock option and ESPP activity compared to $6.4 million in the first six months of the prior year. The large decrease is related to the exercise of stock based awards from executive management turnover that took place in fiscal year 2017.
  • $9.5 million payment on earn-out liabilities in the first six months of fiscal year 2018 compared to $9.9 million in the first six months of fiscal year 2017.
  • $7.8 million from the repurchase of common shares in the first six months of fiscal year 2017. There were no repurchases of common shares in the first six months of fiscal year 2018.

On November 7, 2016, the Company entered into a Credit Agreement that provides for a $100.0 million senior secured term loan facility and a $150.0 million senior secured revolving credit facility, which includes up to a $20.0 million sublimit for letters of credit and a $5.0 million sublimit for swingline loans.

We believe that our current cash and investment balances, together with future cash generated from operations and our revolving credit facility capacity of up to $150.0 million as of November 30, 2017, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make significant acquisitions of other businesses or technologies in the future, we may require additional external financing.

Market risk

As filed, 2,984 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Foreign Currency Exchange Rate Risk

We are exposed to market risk from changes in currency exchange rates, as well as interest rate fluctuations on our credit facility and investments that could impact our results of operations and financial position.

We transact sales in currencies other than the U.S. Dollar, particularly the Euro, British pound and Canadian dollar. Approximately 7% of our sales in the second quarter of fiscal 2018 were denominated in foreign currencies. We do not have expenses denominated in foreign currencies at the level of our sales and as a result, our profitability is exposed to currency fluctuations. When the U.S. Dollar strengthens, our sales and gross profit will be negatively impacted. In addition, we have assets and liabilities denominated in non-functional currencies which are remeasured at each reporting period, with the offset to changes presented as a component of Other (Expenses) Income. Significant non-functional balances include accounts receivable due from a sub-section of our international customers.

Interest Rate Risk

On November 7, 2016, we entered into the Credit Agreement which provides for a $100 million senior secured Term Loan and a $150 million Revolving Facility. Interest on both the Term Loan and Revolving Facility is based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.50% to 2.25% respectively. In the event of default, the interest rate may be increased by 2.0%. A 50 basis point (0.50%) increase or decrease in the interest rate would result approximately in a $2.0 million increase or decrease in interest expense over the life of the agreement.

Concentration of Credit Risk

Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, our credit facility and trade accounts receivable.

The Company maintains cash and cash equivalents at various institutions and performs periodic evaluations of the relative credit standings of these financial institutions to ensure their credit worthiness. In addition, the Credit Agreement is structured across five above investment grade banks. The Company has the ability to draw equally amongst the five banks which limits the concentration of credit risk of one institution.

Concentration of credit risk with respect to trade accounts receivable is limited due to the large number of customers that purchase products from the Company. No single customer represents more than 10% of total sales. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Although the Company does not currently foresee a significant credit risk associated with the outstanding accounts receivable, repayment is dependent upon the financial stability of our customers.

Controls and procedures

As filed, 1,402 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of disclosure controls and procedures

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting for the fiscal quarter ended November 30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

AngioDynamics, Inc. and Subsidiaries

Risk factors

As filed, 684 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2017 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-11-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Gross profit3 months2017-09-01 to 2017-11-30$42.7mus-gaap:GrossProfit
Gross profit6 months2017-06-01 to 2017-11-30$84.0mus-gaap:GrossProfit
Research and development3 months2017-09-01 to 2017-11-30$6.1mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2017-06-01 to 2017-11-30$12.5mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-09-01 to 2017-11-30$1.1mus-gaap:OperatingIncomeLoss
Operating income6 months2017-06-01 to 2017-11-30$1.3mus-gaap:OperatingIncomeLoss
Interest expense3 months2017-09-01 to 2017-11-30$760.0kus-gaap:InterestExpense
Interest expense6 months2017-06-01 to 2017-11-30$1.5mus-gaap:InterestExpense
Income tax3 months2017-09-01 to 2017-11-30−$166.0kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2017-06-01 to 2017-11-30−$147.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2017-09-01 to 2017-11-30$249.0kus-gaap:NetIncomeLoss
Net income6 months2017-06-01 to 2017-11-30$214.0kus-gaap:NetIncomeLoss
Diluted EPS3 months2017-09-01 to 2017-11-30$0.01us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2017-06-01 to 2017-11-30$0.01us-gaap:EarningsPerShareDiluted
Basic EPS3 months2017-09-01 to 2017-11-30$0.01us-gaap:EarningsPerShareBasic
Basic EPS6 months2017-06-01 to 2017-11-30$0.01us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2017-09-01 to 2017-11-3037,383,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2017-06-01 to 2017-11-3037,322,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2017-06-01 to 2017-11-30$13.2mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure6 months2017-06-01 to 2017-11-30$1.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases6 months2017-06-01 to 2017-11-30$0us-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2017-11-30$49.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-11-30$152.5mus-gaap:AssetsCurrent
Total assetsAt period end2017-11-30$697.8mus-gaap:Assets
Current liabilitiesAt period end2017-11-30$59.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-11-30$176.6mus-gaap:Liabilities
Long-term debtAt period end2017-11-30$89.0mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2017-11-30$5.0mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2017-11-30$521.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001275187-18-000003. Last ingested by Listed: Nov 4, 2026, 20:24 ET. Listed shows no prices and gives no investment advice.